Latest News and Press Releases

MINNEAPOLIS, March 20, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the first closing of a...

DM199 may offer an effective and safe treatment with a significantly longer treatment window (24 hours) compared to the current standard of careREMEDY trial lead by prominent neurologist Dr. Bruce...

MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital...

MINNEAPOLIS, Jan. 18, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (TSX VENTURE:DMA) (OTCQB:DMCAF), provides corporate update. As we enter into 2018, we wanted to thank you,...

MINNEAPOLIS, Dec. 21, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF) (the “Company”), today announced that at its Annual General and Special Meeting (the “Meeting”)...

MINNEAPOLIS, Dec. 18, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) announced today the closing of its previously announced non-brokered private...

MINNEAPOLIS, Dec. 13, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF), announces that, subject to TSX Venture Exchange approval, it is undertaking a...

MINNEAPOLIS, Nov. 22, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), announced it has received ethics committee approval to initiate the first...

MINNEAPOLIS, Nov. 20, 2017 (GLOBE NEWSWIRE) -- DiaMedica (TSX-V:DMA) today on behalf of the board of directors announces that in accordance with the terms of the warrant indenture for warrants...

MINNEAPOLIS, Nov. 07, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company focused on improving the lives...